Oncology Medical News about NSCLC, gefitinib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
Lung Cancer, 08/19/09

Tomizawa Y et al. – In a study to investigate the efficacy of gefitinib re-challenge for pts who responded to initial treatment with gefitinib and acquired resistance to gefitinib thereafter, it was concluded that re-administration of gefitinib was effective and thus should be considered as 1 of the treatment options for pts with non-small cell lung cancer (NSCLC) who once responded and acquired resistant to gefitinib following subsequent chemotherapy.

Methods

Medical records were retrospectively reviewed in the hospitals of National Hospital Organization.
Pts histologically or cytologically confirmed NSCLC were eligible if they once responded to initial treatment with gefitinib (CR, PR or SD) and then re-treated with gefitinib following subsequent chemotherapy.

Results

20 pts (16 PR, 4 SD) were enrolled.
After re-treatment with gefitinib, 5 cases showed PR and 8 cases SD.
Overall response rate was 25% (5/20) and disease control rate was 65% (13/20) in gefitinib re-treated pts.
Median survival time from start of initial gefitinib and from start of re-administration of gefitinib were 34.0 and 10.0 mos, respectively.

<< Previous
Second cancers as competing causes of death after radical...

Next >>
Tumour infiltrating lymphocytes in squamous cell carcinoma of the...